76 results
Page 2 of 4
8-K
EX-99.1
nzg29zjc x6jo86w
11 May 23
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
8:31am
8-K
EX-99.1
ycfka ij9f25wac1h2i
17 Apr 23
Candel Therapeutics Receives FDA Fast Track Designation for CAN‑2409 in Non-Small Cell Lung Cancer
8:30am
8-K
c2m1no1f8
17 Apr 23
Candel Therapeutics Receives FDA Fast Track Designation for CAN‑2409 in Non-Small Cell Lung Cancer
8:30am
8-K
EX-99.1
l3svtyk
30 Mar 23
Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights
8:30am
8-K
EX-99.1
8hdvdo rz0fjwo
6 Dec 22
Other Events
5:30pm
8-K
EX-99.1
gwqxlbgqehzf
6 Dec 22
Regulation FD Disclosure
8:01am
8-K
EX-99.1
ux1vbkuvouxsx5qv vf
29 Nov 22
Regulation FD Disclosure
8:31am
8-K
EX-99.1
8hm9no5
18 Nov 22
Other Events
8:30am
8-K
EX-99.1
93hv1a 64o
14 Nov 22
Other Events
9:26am
8-K
EX-99.1
cugjav
10 Nov 22
Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
8:30am
8-K
r0alqp v7y
14 Oct 22
Submission of Matters to a Vote of Security Holders
5:00pm
8-K
EX-99.1
110jhkzjmes mj7z3qu
7 Sep 22
Candel Therapeutics Announces Two Executive Leadership Appointments
8:02am
DEF 14A
1qq aew1xqau6l
2 Sep 22
Definitive proxy
8:30am
S-3
7ykf7z
5 Aug 22
Shelf registration
5:08pm
8-K
EX-99.1
oj5mmawjx00 u3
5 Aug 22
Candel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
8:30am